Welcome to our dedicated page for Brainsway Ltd. SEC filings (Ticker: BRSYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Brainsway Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Brainsway Ltd.'s regulatory disclosures and financial reporting.
BrainsWay Ltd. reported strong Q1 2026 growth and profitability while emphasizing its shift to a high-margin recurring revenue model. Q1 2026 revenue rose 35% year over year to about $15.5 million, with net income more than doubling to roughly $2.3 million and Adjusted EBITDA up 117% to about $2.8 million.
The company shipped a record 117 Deep TMS systems in the quarter, expanding its installed base to roughly 1,820 systems and supporting an ARR-focused lease and pay-per-use model. Remaining performance obligations reached about $75 million and cash was $58 million as of March 31, 2026, with no debt.
BrainsWay reiterated full-year 2026 guidance for revenue of $66–68 million, operating income margin of 13–14%, and Adjusted EBITDA of $12–14 million. The company highlighted expanded reimbursement, new clinical indications under development, and minority investments in mental health providers as additional growth drivers.
BrainsWay Ltd. ownership disclosure: Masters Capital Management, LLC and Michael Masters report beneficial ownership of 1,500,000 Ordinary Shares of BrainsWay Ltd., representing 3.8% of the class. The percent is calculated using 39,165,806 Ordinary Shares outstanding as of December 31, 2025.
The filing is an amendment (Schedule 13G/A, Amendment No. 2) and lists shared voting and dispositive power of 1,500,000 shares held directly by Masters Funds. Signatures are by Michael Masters dated 05/13/2026.
BrainsWay Ltd. reported strong first quarter 2026 results, with revenue up 35% year-over-year to $15.5 million and net income more than doubling to $2.3 million. Adjusted EBITDA rose 117% to $2.8 million, reflecting improved profitability on higher sales.
Remaining performance obligations grew 25% to about $75 million, and the company shipped a record 117 Deep TMS systems, lifting the installed base to roughly 1,820 systems. Management reiterated full-year 2026 guidance for revenue of $66–$68 million, operating income of 13–14% of revenue, and Adjusted EBITDA of $12–$14 million, and ended the quarter with $58.9 million in cash and restricted cash.
BRAINSWAY LTD. amendment to a Schedule 13G/A reports that Harel Insurance Investments & Financial Services Ltd. beneficially owns 2,677,117 Ordinary Shares (reported here as Ordinary Shares) representing 6.8% of the class based on 39,165,806 Ordinary Shares outstanding as of December 31, 2025. The filing breaks down holdings between client/managed accounts and a small proprietary position and is signed by a company officer on 05/04/2026.
BrainsWay Ltd. files its annual report describing a shift to profitability, detailed risk factors and capital needs. The company reports net income of $2.9 million for 2024 and $7.5 million for 2025, but still has an accumulated deficit of $90.8 million as of December 31, 2025.
BrainsWay depends on its Deep TMS systems for depression, OCD and smoking addiction, and highlights risks around physician adoption, competition from other TMS and drug therapies, and reimbursement hurdles. The report also notes supply-chain and geopolitical risks tied to its Israeli manufacturing base and reliance on select large clinic networks.
As of December 31, 2025, BrainsWay had 39,165,806 ordinary shares outstanding and remains reliant on external financing, including a November 2024 private placement, to support growth, clinical trials and further regulatory expansion for Deep TMS.
BrainsWay Ltd. furnished an update highlighting growing U.S. payer support for nurse practitioner‑administered Transcranial Magnetic Stimulation (TMS) therapy, including its Deep TMS™ platform. Optum Behavioral Health revised its TMS policy in late 2025 to let psychiatric mental health nurse practitioners order, supervise, and administer TMS in full‑practice states, covering approximately 34.8 million lives.
BrainsWay notes that other commercial insurers, several Medicare Administrative Contractors, the U.S. Department of Veterans Affairs, and TRICARE West have adopted similar approaches. The company believes broader acceptance of nurse practitioner‑delivered Deep TMS can ease psychiatrist shortages and improve access to non‑drug mental health treatments.
Brainsway Ltd. disclosure: MEITAV Investment House Ltd. reports shared voting and dispositive power over 2,099,637 American Depositary Shares (ADS) representing 5.24% of ordinary shares based on 40,033,028 ordinary shares outstanding as of March 31, 2026.
The filing states the reported ADS are held across subsidiaries and client accounts: 408,408 ordinary shares (1.02%) by Meitav Tachlit Mutual Funds Ltd. and 1,691,229 ordinary shares (4.22%) by Meitav Provident Funds & Pension Ltd. Voting and investment decisions are described as made by each subsidiary under independent management.
BrainsWay Ltd. reports it has completed an additional $6 million milestone-based convertible loan investment in Neurolief Ltd. This second tranche was triggered by U.S. FDA Premarket Approval for Neurolief’s Proliv™Rx system, an at-home neurostimulation therapy for treatment-resistant major depressive disorder.
Including this tranche, BrainsWay has invested $11 million in Neurolief under their August 2025 strategic investment agreement. The arrangement also provides for a potential third tranche of up to a $5 million equity investment tied to Neurolief achieving a defined revenue target, and gives BrainsWay a call option to acquire all outstanding equity interests in Neurolief based on specified valuation formulas.
BrainsWay Ltd. reported that it completed a $1 million milestone-based investment in Axis Management Company, Inc., which services several mental health clinics in Colorado. This investment was triggered after Axis achieved a predefined revenue performance milestone under an August 2025 strategic equity financing agreement between the two companies.
BrainsWay previously made a $2.3 million equity investment in Axis and now holds a minority position in Axis through a preferred, annually compounding security, with a redemption mechanism relating to the shares. The move supports BrainsWay’s strategy of partnering with leading U.S. mental health providers to expand access to advanced neurostimulation treatments.
Brainsway Ltd. director Abraham Zangen filed an initial ownership report showing substantial direct holdings in the company. He holds 905,963 Ordinary Shares, which includes 899,713 shares plus unvested RSUs for 6,250 shares that vest quarterly until March 5, 2028. He also holds stock options over 25,000 Ordinary Shares with an exercise price of NIS 11.17 per share, expiring on March 5, 2034, with the remaining 12,500 options vesting in equal quarterly installments until March 5, 2028. The Ordinary Shares may also be held as American Depositary Shares, each currently representing one Ordinary Share.